Ergocalciferol (ergocalciferol) oral solution 1.25 mg/ml. 10 ml. №1 vial


Manufacturer: Ukraine

For the prevention and treatment of hypovitaminosis D, rickets, as well as bone diseases caused by calcium metabolism disorders (various forms of osteoporosis, osteomalacia), parathyroid gland disorders (tetany), skin and bone tuberculosis, psoriasis, systemic lupus erythematosus (SLE) of the skin and mucous membranes.



Ergocalciferol Storage
active substance: ergocalciferol;

1 ml of solution contains ergocalciferol (vitamin D2) 1.25 mg (50,000 IU);

Ergocalciferol excipient: sunflower oil.

Ergocalciferol Dosage form
The solution is oral, oily.

Main physical and chemical properties: clear oily liquid from light yellow to dark yellow color, without bitter taste. The presence of a specific odor is allowed. The activity of ergocalciferol is expressed in international units: 0.025 μg of chemically pure vitamin D2 corresponds to 1 IU.

Pharmacotherapeutic group
Preparations of vitamin D and its analogues. ATX code A11C C01.

Pharmacological properties
Ergocalciferol (vitamin D2) regulates the metabolism of phosphorus and calcium in the body, promotes their absorption in the intestine by increasing the permeability of its mucous membrane and adequate deposition in bone tissue. The effect of ergocalciferol is enhanced by the simultaneous intake of calcium and phosphorus compounds.


Vitamin D2 belongs to the group of vitamins soluble in oils and is one of the regulators of phosphorus and calcium metabolism. Promotes the absorption of the latter from the intestine, distribution and deposition in the bones during their growth. The specific effect of the vitamin is especially evident in rickets (anti-rickets vitamin).


Orally taken vitamin D is absorbed into the blood in the small intestine, especially well – in its proximal part. With the blood, the vitamin enters the liver cells, where it is hydroxylated with the participation of 25-hydroxylase to form its transport form, which is delivered by the blood to the mitochondria of the kidneys. In the kidneys, it is further hydroxylated with l α-hydroxylase, resulting in the formation of a hormonal form of the vitamin. Already this form of vitamin D is transported by blood to target tissues, for example – in the intestinal mucosa, where it initiates the absorption of Ca2 +.

For the prevention and treatment of hypovitaminosis D, rickets, as well as bone diseases caused by disorders of calcium metabolism (various forms of osteoporosis, osteomalacia), parathyroid dysfunction (tetany), tuberculosis of the skin and bones, psoriasis, systemic lupus erythematosus and mucous membranes.

Hypersensitivity to the components of the drug;
hypervitaminosis D;
active form of pulmonary tuberculosis;
peptic ulcer of the stomach and duodenum;
acute and chronic diseases of the liver and kidneys;
organic diseases of the heart and blood vessels in the stage of decompensation;
elevated levels of calcium and phosphorus in the blood and urine;